Abramson Cancer Center at Penn Medicine
This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant.
Hepatocellular Carcinoma
INCB099280
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 15 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Pilot Study of Neoadjuvant INCB099280 in Patients With Hepatocellular Carcinoma Awaiting Liver Transplant |
Actual Study Start Date : | May 1, 2024 |
Estimated Primary Completion Date : | May 1, 2027 |
Estimated Study Completion Date : | September 1, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: INCB099280 Study participants will receive the recommended phase II dose (400mg/kg) of INCB099280 orally on days 1 through 28 of each 28-day cycle until liver transplant. |
Drug: INCB099280 |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104